Uniqure (NASDAQ:QURE) Hits New 1-Year High at $77.07

Uniqure NV (NASDAQ:QURE)’s share price reached a new 52-week high on Monday . The stock traded as high as $77.07 and last traded at $74.77, with a volume of 8049 shares trading hands. The stock had previously closed at $75.55.

Several equities analysts have recently weighed in on the stock. Janney Montgomery Scott reaffirmed a “buy” rating on shares of Uniqure in a report on Tuesday. BidaskClub raised shares of Uniqure from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 13th. Wells Fargo & Co lifted their price target on shares of Uniqure from $65.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. Cantor Fitzgerald set a $81.00 price target on shares of Uniqure and gave the company a “buy” rating in a research note on Friday, May 10th. Finally, SunTrust Banks lifted their price target on shares of Uniqure to $76.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $75.82.

The company has a market cap of $2.83 billion, a PE ratio of -28.19 and a beta of 0.95. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38.

Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.03). Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $2.00 million. As a group, research analysts anticipate that Uniqure NV will post -3.01 earnings per share for the current year.

In other Uniqure news, Director Philip Astley-Sparke sold 6,000 shares of Uniqure stock in a transaction on Monday, April 1st. The shares were sold at an average price of $59.84, for a total transaction of $359,040.00. Following the sale, the director now owns 19,272 shares of the company’s stock, valued at approximately $1,153,236.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $58.38, for a total transaction of $467,040.00. Following the sale, the chief executive officer now directly owns 421,730 shares in the company, valued at approximately $24,620,597.40. The disclosure for this sale can be found here. Insiders sold a total of 88,922 shares of company stock worth $5,605,629 in the last three months. 2.91% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. Bank of New York Mellon Corp boosted its position in shares of Uniqure by 12.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock valued at $682,000 after acquiring an additional 2,129 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Uniqure by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after acquiring an additional 3,992 shares during the last quarter. Vanguard Group Inc boosted its position in shares of Uniqure by 4.1% during the 3rd quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after acquiring an additional 3,992 shares during the last quarter. Advisor Group Inc. boosted its position in shares of Uniqure by 5.3% during the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 502 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Uniqure by 2.5% during the 4th quarter. Northern Trust Corp now owns 33,086 shares of the biotechnology company’s stock valued at $954,000 after acquiring an additional 797 shares during the last quarter. 60.12% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was first published by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.wkrb13.com/2019/06/12/uniqure-nasdaqqure-hits-new-1-year-high-at-77-07.html.

About Uniqure (NASDAQ:QURE)

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: How does a security become overbought?

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.